IVERIC bio Inc (ISEE) Stock Price, Forecast & Analysis
NASDAQ:ISEE • US46583P1021
ISEE Key Statistics, Chart & Performance
The current stock price of ISEE is 39.95 USD. In the past month the price increased by 4.55%. In the past year, price increased by 241.45%.
ISEE Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ISEE. When comparing the yearly performance of all stocks, ISEE is one of the better performing stocks in the market, outperforming 99.25% of all stocks.
ISEE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ISEE. ISEE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ISEE Financial Highlights
Over the last trailing twelve months ISEE reported a non-GAAP Earnings per Share(EPS) of -1.76. The EPS decreased by -55.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.2 |
ISEE Forecast & Estimates
14 analysts have analysed ISEE and the average price target is 39.88 USD. This implies a price decrease of -0.17% is expected in the next year compared to the current price of 39.95.
ISEE Ownership
ISEE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.94 | 409.148B | ||
| AMGN | AMGEN INC | 16.38 | 198.801B | ||
| GILD | GILEAD SCIENCES INC | 17.38 | 192.281B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.11 | 124.696B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.29 | 84.911B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.93 | 41.535B | ||
| INSM | INSMED INC | N/A | 31.724B | ||
| BIIB | BIOGEN INC | 12.92 | 28.841B | ||
| NTRA | NATERA INC | N/A | 28.695B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.07 | 20.396B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ISEE
Company Profile
IVERIC bio, Inc. operates as a biopharmaceutical company. The company is headquartered in Parsippany, New Jersey and currently employs 74 full-time employees. The company went IPO on 2013-09-25. The firm is focused on the discovery and development of treatments for retinal diseases with unmet medical needs. Its lead asset is its clinical-stage product candidate, avacincaptad pegol, which is also referred to as ACP or Zimura, a complement C5 inhibitor. Zimura is targeting diseases including geographic atrophy (GA), intermediate age-related macular degeneration (AMD), and autosomal recessive Stargardt disease (STGD1). In addition to ACP, the Company is also developing its preclinical product candidate, IC-500, a high temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA secondary to AMD and potentially other age-related retinal diseases. Its portfolio also includes several ongoing gene therapy research programs, each of which uses adeno-associated virus (AAV) for gene delivery. These AAV mediated gene therapy programs are targeting the orphan inherited retinal diseases (IRDs).
Company Info
IVERIC bio Inc
8 Sylvan Way, Suite 2372
Parsippany NEW JERSEY 10001 US
CEO: Glenn P. Sblendorio
Employees: 74
Phone: 16094746755.0
IVERIC bio Inc / ISEE FAQ
What does IVERIC bio Inc do?
IVERIC bio, Inc. operates as a biopharmaceutical company. The company is headquartered in Parsippany, New Jersey and currently employs 74 full-time employees. The company went IPO on 2013-09-25. The firm is focused on the discovery and development of treatments for retinal diseases with unmet medical needs. Its lead asset is its clinical-stage product candidate, avacincaptad pegol, which is also referred to as ACP or Zimura, a complement C5 inhibitor. Zimura is targeting diseases including geographic atrophy (GA), intermediate age-related macular degeneration (AMD), and autosomal recessive Stargardt disease (STGD1). In addition to ACP, the Company is also developing its preclinical product candidate, IC-500, a high temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA secondary to AMD and potentially other age-related retinal diseases. Its portfolio also includes several ongoing gene therapy research programs, each of which uses adeno-associated virus (AAV) for gene delivery. These AAV mediated gene therapy programs are targeting the orphan inherited retinal diseases (IRDs).
Can you provide the latest stock price for IVERIC bio Inc?
The current stock price of ISEE is 39.95 USD. The price increased by 0.38% in the last trading session.
Does IVERIC bio Inc pay dividends?
ISEE does not pay a dividend.
What is the ChartMill rating of IVERIC bio Inc stock?
ISEE has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is IVERIC bio Inc (ISEE) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ISEE.
Can you provide the market cap for IVERIC bio Inc?
IVERIC bio Inc (ISEE) has a market capitalization of 5.51B USD. This makes ISEE a Mid Cap stock.